Showing 850 results
-
Media Release /The new product joins the #1 doctor recommended Systane family of dry eye drops as the brand's most advanced solution to dateAlcon launches multimedia campaign to reach the 30 million people living…
-
Media Release /- New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)(1)- In a landmark…
-
Media Release /- Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy…
-
Media Release /- Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)1-…
-
Media Release /- Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States- Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-related…
-
Media Release /Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable (1)Patients had a 65% chance of being relapse-free…
-
Media Release /-- Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%)-- About two-thirds of…
-
Media Release /- Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line…
-
Media Release /- The My Migraine Voice survey involved more than 11,000 people globally, 10% of which were from the US, and highlights urgent need for better care for benefit of patients and society- In the US,…
-
Media Release /- New prescribing information to include data demonstrating Cosentyx® (secukinumab) slows progression of joint structural damage associated with psoriatic arthritis (PsA) at Week 24(1)- PsA can lead…
